SINGAPORE, Oct. 17, 2022 /PRNewswire/ — GenScript ProBio (a world one-stop CDMO from GenScript Group) today announced a strategic collaboration with Hibiocy Co. Ltd., a non-public corporation based in Bangkok, Thailand, to speed up a respiratory-care medical device, COVITRAP™ which comprises human antibody for Covid-19 inhibiting project.
COVITRAP™ is a nasal spray which is able to stopping the Covid-19 virus from attaching to the interior surfaces of the nasal cavity, thus reduces the viral load within the cavity. COVITRAP™ was successfully approved by Thai FDA and was officially launched in Thailand market. Hibiocy is working to launch the COVITRAP™ nasal spray device on other countries as well. GenScript ProBio will probably be the exclusive service partner for the upcoming industrial manufacturing.
Each parties are committed to the invention of human antibody that may bind to the Covid-19 virus and effectively inhibit infections, which is a component of the important thing element within the COVITRAP™ nasal spray device. This partnership will leverage synergies within the complementary strengths and capabilities from each research and discovery units using their next-generation technologies to speed up the event of revolutionary and highly effective respiratory-care solutions against Covid-19 virus, from goal identification to industrial manufacturing. The COVITRAP™ device will bring profit to the general public by offering extra protection against the Covid-19 virus. Except for the COVITRAP™ project, each parties are dedicated to set off a future long run collaboration for brand new product and manufacturing in near future.
GenScript ProBio, a world one-stop CDMO from GenScript Group focuses on single B cell, phage display, hybridoma, fully human and bispecific antibody technologies, commits to facilitate biological drugs from discovery to development and industrial use. Under this agreement, GenScript ProBio will constantly be the exclusive service partner from clinical material manufacturing to industrial manufacturing and supply skilled consultation to Hibiocy for future recent products. Top priority to access GMP service will probably be granted to Hibiocy to speed up the antibody drug development.
“This collaboration with GenScript on this ground-breaking discovery behind the event of revolutionary respiratory-care medical device with human antibody for inhibiting Covid-19 is critical given the growing concern of Covid-19 impacting every day life in addition to unknown long Covid-19 impacts and more uncertain conditions from infections. We imagine this discovery and collaboration with GenScript will bring global revolutionary solution with a shiny opportunity for us to guard and save more lives from either getting infected or reinfected from recent variances of Covid-19. Ultimately, this life changing solution will bring back a traditional life for everybody.” Ms. Worrawan Chaikamnerd, CEO at Hibiocy and KISS said.
“At GenScript, we’re resolute in our commitment to advancing human health as a part of our mission to save lots of and improve lives,” said Mr. Johnson Wang, President of GenScript Asia Pacific. “We imagine the Covid-19 nasal spray device represents a promising approach to combating the novel coronavirus pandemic and can bring profit to the general public. This collaboration with Hibiocy brings together two firms dedicated to the fight against Covid-19 to utilize our joint capabilities in complementary and synergistic ways to handle this difficult global health challenge.”
GenScript ProBio – Biologics CDMO
GenScript ProBio is the subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, skilled solutions and efficient processes in cell and gene therapy (CGT), vaccine, biologics discovery and antibody protein drug to speed up drug development for purchasers. GenScript ProBio has established firms in america, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in america, Europe, Asia Pacific and other regions to acquire greater than 30 IND approvals.
GenScript ProBio’s total cell and gene therapy solution covers CMC of plasmid and virus for IND filing in addition to clinical manufacturing and industrial manufacturing. GenScript ProBio’s revolutionary solutions for biologics discovery and development include therapeutic antibody discovery, antibody engineering and antibody characterization. In biologics development service, GenScript ProBio has built a DNA to GMP material platform, including stable cell line development, host cell license, process development, analytical development to clinical manufacturing, and offer fed-batch and perfusion process to satisfy the growing needs for antibody and protein drugs. GenScript ProBio has established GMP capability which meets FDA, EMA and NMPA regulatory requirements.
Toward the mission of “Innovation through Collaboration”, GenScript ProBio is committed to helping customers shorten the timeline for the event of biological drugs from discovery to commercialization, significantly lowering R&D costs and constructing a healthier future.
About Hibiocy Co. Ltd
Hibiocy Co. Ltd is a non-public corporation based in Bangkok, Thailand, the affiliate of Rojukiss International Public Company Limited (KISS) – the leading Thai-based Beauty & Health company. Hibiocy is established to guide the sourcing, procuring and manufacturing the Anti-COVID nasal spray, trade-name “Vaill COVITRAP”, and future recent products in healthcare business.
Hibiocy is a newly established organization in Thailand that collaboratively works with key leading partners including Health Systems Research Institute (HSRI), the Faculty of Medicine at Chulalongkorn University, the Faculty of Pharmacy at Silpakorn University and the Government Pharmaceutical Organization (GPO) in jointly developed an anti-COVID nasal spray, a ground breaking innovation that fully approved by Thai FDA and commercialized since early October this 12 months.
SOURCE Genscript
